Sopharma AD reports sale of treasury shares worth BGN 244,852

Ognian Ivanov Donev
Ognian Ivanov Donev
0Comments

Sopharma AD has announced the sale of 99,775 treasury shares on August 22, 2025. The transaction represents 0.02% of the company’s share capital and was executed on the Bulgarian Stock Exchange for a total value of BGN 244,852.50. The average price per share was BGN 2.45.

Following this sale, Sopharma AD holds a total of 20,848,882 treasury shares, which account for 3.87% of its share capital.

“Sopharma” AD (SFA: Bulgarian Stock Exchange, SPH: Warsaw Stock Exchange) notifies that on August 22, 2025 the Company sold 99 775 (ninety-nine thousand seven hundred and seventy-five) treasury shares representing 0.02% of the share capital of the Company, at a total value of BGN 244 852.50 on the Bulgarian Stock Exchange, the average price per share was BGN 2.45.”

The company made this disclosure in accordance with Article 17 of Regulation (EU) No 596/2014 by the European Parliament and Council.

The remaining number of treasury shares after this transaction is reported as part of regulatory requirements.



Related

Paul Hudson Chief Executive Officer Sanofi SA

Acoziborole receives key EU panel backing as single-dose treatment for sleeping sickness

Acoziborole Winthrop, a new oral treatment for sleeping sickness developed by the Drugs for Neglected Diseases initiative (DNDi) and Sanofi, has received a positive opinion from the European Medicines Agency’s Committee for Medicinal Products for…

Martin Lundstedt President and CEO at Volvo Group North America LLC Volvo Group North America LLC

Volvo announces updated share and vote count after series conversion

The number of votes in AB Volvo has changed following the conversion of 2,000,619 Series A shares into an equal number of Series B shares.

Paul Hudson Chief Executive Officer Sanofi SA

Sanofi and Regeneron’s Dupixent recommended for EU approval in young children with chronic urticaria

Sanofi and Regeneron have announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has issued a positive opinion recommending approval of Dupixent (dupilumab) for children aged two to 11 years with…

Trending

The Weekly Newsletter

Sign-up for the Weekly Newsletter from EU Business Daily.